文献速递心脑血管急症重症综合管理与镇静镇痛

高风险患者中达到的血压与心血管结局:ONTARGET与TRANSCEND试验结果

Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
PubMed 文献 · Lancet · 2017-04-05
一句话结论在高危心血管病患者中,治疗达到的平均收缩压低于120 mm Hg或舒张压低于70 mm Hg与心血管事件风险增加相关,提示血压并非越低越好。

该分析基于ONTARGET和TRANSCEND两项随机试验的30937例高危心血管病患者(70%有高血压),中位随访56个月。分析治疗期间平均血压、基线血压及时间更新血压与复合心血管结局及其组分的关系。结果显示治疗期间平均收缩压低于120 mm Hg者复合心血管结局(HR 1.14,95%CI 1.03-1.26)、心血管死亡(HR 1.29,95%CI 1.12-1.49)和全因死亡(HR 1.28,95%CI 1.15-1.42)风险高于收缩压120-140 mm Hg者;平均舒张压低于70 mm Hg者复合结局(HR 1.31,95%CI 1.20-1.42)、心肌梗死(HR 1.55,95%CI 1.33-1.80)、心衰住院(HR 1.59,95%CI 1.36-1.86)和全因死亡(HR 1.16,95%CI 1.06-1.28)风险高于舒张压70-80 mm Hg者。作者认为高危患者最低血压不一定是理想目标,但不能排除反向因果。

要点

  • 治疗期间平均收缩压低于120 mm Hg(n=4052)者复合心血管结局HR 1.14(95%CI 1.03-1.26)、心血管死亡HR 1.29(95%CI 1.12-1.49)、全因死亡HR 1.28(95%CI 1.15-1.42),均高于收缩压120-140 mm Hg者(n=16099,参照HR 1)。
  • 治疗期间平均舒张压低于70 mm Hg(n=5352)者复合结局HR 1.31(95%CI 1.20-1.42)、心肌梗死HR 1.55(95%CI 1.33-1.80)、心衰住院HR 1.59(95%CI 1.36-1.86)、全因死亡HR 1.16(95%CI 1.06-1.28),均高于舒张压70-80 mm Hg者(n=14305)。
  • 平均治疗收缩压约130 mm Hg时风险最低;平均收缩压110-120 mm Hg时复合结局、心血管死亡和全因死亡风险增加,但卒中除外。
  • 基线收缩压≥140 mm Hg者所有结局发生率高于120至<140 mm Hg者;基线舒张压<70 mm Hg者多数结局风险最高。
  • 治疗期间平均收缩压低于120 mm Hg对心肌梗死、卒中、心衰住院无获益也无害;平均舒张压低于70 mm Hg则心肌梗死和心衰住院风险增加。

适用人群与场景

  • 年龄55岁及以上、有心血管疾病史的高危患者,其中70%有高血压;来自ONTARGET和TRANSCEND试验人群。
  • ONTARGET纳入对ACE抑制剂耐受的患者;TRANSCEND纳入对ACE抑制剂不耐受的患者。

处置流程与药物剂量

  • ONTARGET:经过导入期后随机口服雷米普利10 mg/日(n=8407)、替米沙坦80 mg/日(n=8386)或两者联合(n=8334)。
  • TRANSCEND:随机口服替米沙坦80 mg/日(n=2903)或安慰剂(n=2907)。

研究设计与关键结果

  • 研究类型:对ONTARGET和TRANSCEND两项随机试验的事后分析;共30937例患者,来自40个国家733个中心,中位随访56个月。
  • ONTARGET招募时间2001年12月1日至2008年7月31日;TRANSCEND招募时间2001年11月1日至2004年5月30日。
  • 与治疗期间收缩压120-140 mm Hg者(n=16099,参照HR 1)相比,收缩压低于120 mm Hg者(n=4052)复合心血管结局 adjusted HR 1.14(95%CI 1.03-1.26)、心血管死亡HR 1.29(95%CI 1.12-1.49)、全因死亡HR 1.28(95%CI 1.15-1.42);心肌梗死、卒中、心衰住院无获益也无害。
  • 平均治疗收缩压约130 mm Hg时风险最低;平均收缩压110-120 mm Hg时复合结局、心血管死亡和全因死亡风险增加,卒中除外。
  • 与治疗期间舒张压70-80 mm Hg者(n=14305)相比,舒张压低于70 mm Hg者(n=5352)复合主要结局HR 1.31(95%CI 1.20-1.42)、心肌梗死HR 1.55(95%CI 1.33-1.80)、心衰住院HR 1.59(95%CI 1.36-1.86)、全因死亡HR 1.16(95%CI 1.06-1.28)。
  • 治疗前和治疗期间平均舒张压约75 mm Hg时风险最低。
  • 基线收缩压≥140 mm Hg者所有结局发生率高于基线收缩压120至<140 mm Hg者;基线舒张压<70 mm Hg者多数结局风险最高。

证据类型、等级与局限

  • 证据类型:对两项随机试验(ONTARGET、TRANSCEND)的事后分析。
  • 局限:原文指出不能排除反向因果的某些影响。

对床旁实践的改变

  • 作者认为,治疗达到的血压极低与多种心血管事件风险增加相关,高危患者最低血压不一定是理想目标。
  • 作者指出,治疗期间平均收缩压低于120 mm Hg与心血管结局风险增加相关(心肌梗死和卒中除外);平均舒张压低于70 mm Hg与复合结局、心肌梗死、心衰住院和全因死亡风险增加相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Studies have challenged the appropriateness of accepted blood pressure targets. We hypothesised that different levels of low blood pressure are associated with benefit for some, but harm for other outcomes.

METHODS: In this analysis, we assessed the previously reported outcome data from high-risk patients aged 55 years or older with a history of cardiovascular disease, 70% of whom had hypertension, from the ONTARGET and TRANSCEND trials investigating ramipril, telmisartan, and their combination, with a median follow-up of 56 months. Detailed descriptions of randomisation and intervention have already been reported. We analysed the associations between mean blood pressure achieved on treatment; prerandomisation baseline blood pressure; or time-updated blood pressure (last on treatment value before an event) on the composite outcome of cardiovascular death, myocardial infarction, stroke, and hospital admission for heart failure; the components of the composite outcome; and all-cause death. Analysis was done by Cox regression analysis, ANOVA, and χ2. These trials were registered with ClinicalTrials.gov, number NCT00153101.

FINDINGS: Recruitment for ONTARGET took place between Dec 1, 2001, and July 31, 2008. TRANSCEND took place between Nov 1, 2001, and May 30, 2004. 30 937 patients were recruited from 733 centres in 40 countries and followed up for a median of 56 months. In ONTARGET, 25 127 patients known to be tolerant to angiotensin-converting-enzyme (ACE)-inhibitors were randomly assigned after a run-in period to oral ramipril 10 mg/day (n=8407), telmisartan 80 mg/day (n=8386), or the combination of both (n=8334). In TRANSCEND, 5810 patients who were intolerant to ACE-inhibitors were randomly assigned to oral telmisartan 80 mg/day (n=2903) or placebo (n=2907). Baseline systolic blood pressure (SBP) 140 mm Hg or higher was associated with greater incidence of all outcomes compared with 120 mm Hg to less than 140 mm Hg. By contrast, a baseline diastolic blood pressure (DBP) less than 70 mm Hg was associated with the highest risk for most outcomes compared with all DBP categories 70 mm Hg or more. In 4052 patients with SBP less than 120 mm Hg on treatment, the risk of the composite cardiovascular outcome (adjusted hazard ratio [HR] 1·14, 95% CI 1·03-1·26), cardiovascular death (1·29, 1·12-1·49), and all deaths (1·28, 1·15-1·42) were increased compared with those in whom SBP was 120-140 mm Hg during treatment (HR 1 for all outcomes, n=16099). No harm or benefit was observed for myocardial infarction, stroke, or hospital admission for heart failure. Mean achieved SBP more accurately predicted outcomes than baseline or time-updated SBP, and was associated with the lowest risk at approximately 130 mm Hg, and at 110-120 mm Hg risk increased for the combined outcome, cardiovascular death, and all-cause death except stroke. A mean DBP less than 70 mm Hg (n=5352) during treatment was associated with greater risk of the composite primary outcome (HR 1·31, 95% CI 1·20-1·42), myocardial infarction (1·55, 1·33-1·80), hospital admission for heart failure (1·59, 1·36-1·86) and all-cause death (1·16, 1·06-1·28) than a DBP 70-80 mm Hg (14 305). A pretreatment and mean on-treatment DBP of about 75 mm Hg was associated with the lowest risk.

INTERPRETATION: Mean achieved SBP less than 120 mm Hg during treatment was associated with increased risk of cardiovascular outcomes except for myocardial infarction and stroke. Similar patterns were observed for DBP less than 70 mm Hg, plus increased risk for myocardial infarction and hospital admission for heart failure. Very low blood pressure achieved on treatment was associated with increased risks of several cardiovascular disease events. These data suggest that the lowest blood pressure possible is not necessarily the optimal target for high-risk patients, although it is not possible to rule out some effect of reverse causality.

FUNDING: Boehringer Ingelheim.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Böhm M, Schumacher H, Teo KK, et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017. PMID: 28390695. doi:10.1016/S0140-6736(17)30754-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。